KW-8232 free base

目录号: GC31633纯度: >98%

KW-8232freebase是一种抗骨质疏松剂，可以减少前列腺素PGE2的生物合成。

Cas No.: 170365-25-0

规格	价格	库存	数量	操作
1 mg	¥7,650.00	现货	1

电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例

Nature
641, 529–536 (2025)
Nature
628, 630–638 (2024)
Nature
632, 686–694 (2024)
Nature
618, 1017–1023 (2023)
Nature
610, 366–372 (2022)
Cell
187(9):2288-2304 (2024)
Cell
183(7):1867-1883 (2020)
Science
388(6745) (2025)
Science
387(6739) (2025)
Science
387(6734) (2025)
Cell Research
35, 97–116 (2025)
Cell Research
34, 683–706 (2024)
Cell Research
33, 273–287 (2023)
Cell Research
33, 546–561 (2023)
Cell Research
33, 904–922 (2023)
Cell Research
31, 1291–1307 (2021)

产品描述 Description

KW-8232 free base is an anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.

KW-8232 free base is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE2 in mouse osteoblastic cells[1].

KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production[1].

[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3.

实验参考方法 Experimental Reference Method

Animal experiment:

After male Sprague-Dawley rats (5-week-old) are anesthetized with sodium pentobarbital (30 mg/kg, i.p.), a dorsolateral incision is made on the right hip through which the sciatic nerve is exposed, and a 0.5-cm section is excised. The contralateral leg is left intact. KW-8232 is dissolved in distilled water and administered orally at 1, 3, 10, and 30 mg/kg once daily beginning 1 day prior to neurectomy. On day 28, rats are exsanguinated under diethyl ether agter obtaining urine, and their femurs are removed. Bone mineral density (BMD) is determined by dual energy x-ray absorptiometry. Twenty-four hour urine samples are collected from the animals, which are fasted immediately after the final administration of KW-8232[1].

References:

[1]. Uchii M, et al. Effect of KW-8232, a novel anti-osteoporotic agent, on bone loss in sciatic neurectomized rats. Jpn J Pharmacol. 1998 Oct;78(2):241-3.

产品文档 Product Documents

Purity:>98%

COA SDS Data Sheet

化学性质Chemical Properties

CAS 号

170365-25-0

SMILES

O=C(C(N1CCN(C)C)=C(C(C2=CC=C(O)C=C2)C3=CC=C(O)C=C3)C4=C1C=CC=C4)N5CCN(C6=CC=CC=C6Cl)CC5

分子式

C₃₆H₃₇ClN₄O₃

分子量

609.16 g/mol

溶解性

Soluble in DMSO

保存条件

Store at -20°C

General tips

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。

Shipping Condition

评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

质量 (Mass)

体积 (Volume)

浓度 (Concentration)

分子量 (MW)

g/mol